Leora Horn

17.4k total citations · 4 hit papers
147 papers, 6.5k citations indexed

About

Leora Horn is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Leora Horn has authored 147 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Oncology, 90 papers in Pulmonary and Respiratory Medicine and 40 papers in Molecular Biology. Recurrent topics in Leora Horn's work include Lung Cancer Treatments and Mutations (82 papers), Lung Cancer Research Studies (66 papers) and Cancer therapeutics and mechanisms (28 papers). Leora Horn is often cited by papers focused on Lung Cancer Treatments and Mutations (82 papers), Lung Cancer Research Studies (66 papers) and Cancer therapeutics and mechanisms (28 papers). Leora Horn collaborates with scholars based in United States, Germany and Spain. Leora Horn's co-authors include Myung‐Ju Ahn, Suresh S. Ramalingam, Enriqueta Felip, Yuichiro Ohe, Sang-We Kim, James Chih‐Hsin Yang, Dong‐Wan Kim, Pasi A. Jänne, Wade T. Iams and Mireille Cantarini and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Leora Horn

142 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

2015 1.6k citations Myung‐Ju Ahn, Sang-We Kim et al. profile →
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

2021 484 citations Stephen V. Liu, Martin Reck et al. Journal of Clinical Oncology profile →
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

2016 397 citations Martin Reck, Alexander Luft et al. Journal of Clinical Oncology profile →
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

2020 303 citations Geoffrey R. Oxnard, Helena A. Yu et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Leora Horn

Since Specialization

Citations

This map shows the geographic impact of Leora Horn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leora Horn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leora Horn more than expected).

Fields of papers citing papers by Leora Horn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leora Horn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leora Horn. The network helps show where Leora Horn may publish in the future.

Co-authorship network of co-authors of Leora Horn

This figure shows the co-authorship network connecting the top 25 collaborators of Leora Horn. A scholar is included among the top collaborators of Leora Horn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leora Horn. Leora Horn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development, Review, and Activation of Thoracic Oncology Investigator-Initiated Trials 2025 ·Clinical Cancer Research ·David E. Gerber, (unknown), Tanushree Prasad, (unknown), Song Zhang, Thomas E. Stinchcombe, Liza C. Villaruz, Joshua Bauml, Wade T. Iams, Tejas Patil, Stephen V. Liu, Leora Horn, (unknown), D. Ross Camidge	1
2	PP01.82 Tumor-Naïve Pre-Surgical ctDNA Detection is Prognostic in Stage I Lung Adenocarcinoma (LUAD), Associating with PD-L1 Positivity and High-Grade Histological Subtype 2024 ·Journal of Thoracic Oncology ·Tae Hee Hong, Soohyun Hwang, Chris Abbosh, Abhijit Dasgupta, Violeta Beleva Guthrie, Tiffany Hung, Joerg Bredno, Jill Walker, Xiaojin Shi, Tsveta Milenkova, Leora Horn, Joon Young Choi, Ho Yun Lee, Jong Ho Cho, Yong Soo Choi, Young Mog Shim, Darren Hodgson, Hong Kwan Kim, Myung‐Ju Ahn	0
3	Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC). 2024 ·Journal of Clinical Oncology ·Mitchell S. von Itzstein, Timothy F. Burns, Jonathan E. Dowell, Leora Horn, David Ross Camidge, Sally J. York, Keith D. Eaton, Christopher J. Walker, Song Zhang, David E. Gerber	1
4	Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS -Mutant Non–Small Cell Lung Cancer 2024 ·Clinical Cancer Research ·Mitchell S. von Itzstein, Timothy F. Burns, Jonathan E. Dowell, Leora Horn, D. Ross Camidge, Sally J. York, Keith D. Eaton, (unknown), Farjana Fattah, (unknown), (unknown), Arjun Gupta, (unknown), Ang Gao, Song Zhang, David E. Gerber	1
5	Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer 2024 ·Trends in cancer ·Chris Abbosh, Darren Hodgson, Gary J. Doherty, Davina Gale, James R. Black, Leora Horn, Jorge S. Reis‐Filho, Charles Swanton	18
6	Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) breakdown → 2021 ·Journal of Clinical Oncology ·Stephen V. Liu, Martin Reck, Aaron S. Mansfield, Tony Mok, Arnaud Scherpereel, Niels Reinmuth, Marina Chiara Garassino, Javier de Castro, Raffaele Califano, Makoto Nishio, Francesco Orlandi, Jorge Alatorre-Alexander, Ticiana Leal, Ying Cheng, Jong Seok Lee, Sivuonthanh Lam, Mark L. McCleland, Yu Deng, See Phan, Leora Horn	484
7	P1.14-32 Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer Patients Treated with Ensartinib 2019 ·Journal of Thoracic Oncology ·Heather A. Wakelee, Karen L. Reckamp, Ticiana Leal, Alberto Chiappori, Saiama N. Waqar, (unknown), Joel W. Neal, (unknown), Kimberly Harrow, (unknown), (unknown), Giovanni Selvaggi, Leora Horn	2
8	EP1.12-06 New Treatment Option for ES-SCLC: Patient Characteristics and Use of an Atezolizumab Regimen in the Real-World Setting 2019 ·Journal of Thoracic Oncology ·Steve McCune, (unknown), (unknown), (unknown), Leora Horn, Ivor Percent, Tarek Mekhail, Jerome H. Goldschmidt, Ticiana Leal, Gary R. MacVicar, Fadi Braiteh, Davey B. Daniel, Maen Hussein, Aaron S. Mansfield, Sivuonthanh Lam, Ann Johnson, S. Morris, Alexander I. Spira	1
9	IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC) 2018 ·Annals of Oncology ·Tony Mok, Martin Reck, Leora Horn, S. Lam, David S. Shames, (unknown), Fairooz F. Kabbinavar, Lin Wang, A. Sandler, Stephen V. Liu	8
10	OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403 2018 ·Journal of Thoracic Oncology ·Sarah B. Goldberg, Mary W. Redman, Rogério Lilenbaum, Katerina Politi, Thomas E. Stinchcombe, Leora Horn, (unknown), Sandeep H. Mashru, Scott Gettinger, Mary Ann Melnick, Jieling Miao, James Moon, Karen Kelly, David R. Gandara	5
11	A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations 2017 ·Clinical Cancer Research ·Helena A. Yu, Alexander I. Spira, Leora Horn, Jared Weiss, Howard West, Giuseppe Giaccone, Tracey L. Evans, Ronan J. Kelly, (unknown), Andrew Krivoshik, Diarmuid Moran, Srinivasu Poondru, Fei Jie, (unknown), Anne Keating, Geoffrey R. Oxnard	23
12	P3.02c-024 Detection of Novel Activating FGFR Rearrangements, Truncations, and Splice Site Alterations in NSCLC by Comprehensive Genomic Profiling 2017 ·Journal of Thoracic Oncology ·Shirish M. Gadgeel, Adrienne Johnson, Leora Horn, Christine M. Lovly, Jonathan W. Riess, Paulo Vidal Campregher, Philip Stephens, Jeffrey A. Ross, Vincent A. Miller, (unknown), Siraj M. Ali, Alexa B. Schrock	1
13	P3.02b-052 Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG S1403 2017 ·Journal of Thoracic Oncology ·Sarah B. Goldberg, James Moon, Rogério Lilenbaum, Katerina Politi, Mary Ann Melnick, Thomas E. Stinchcombe, Leora Horn, (unknown), Jieling Miao, Mary W. Redman, Karen Kelly, David R. Gandara	1
14	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer breakdown → 2016 ·Journal of Clinical Oncology ·Martin Reck, Alexander Luft, Aleksandra Szczęsna, Libor Havel, Sang-We Kim, Wallace Akerley, M. Catherine Pietanza, Yi‐Long Wu, Christoph Zielinski, Michael J. Thomas, Enriqueta Felip, Kathryn A. Gold, Leora Horn, Joachim G.J.V. Aerts, Kazuhiko Nakagawa, Paul Lorigan, Anne Pieters, (unknown), Justin Fairchild, David R. Spigel	397
15	P1.44 (also presented as PD2.02): Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK+ NSCLC 2016 ·Journal of Thoracic Oncology ·(unknown), Heather A. Wakelee, Jeffrey R. Infante, George R. Blumenschein, Karen L. Reckamp, Corey Carter, Saiama N. Waqar, Jon P. Gockerman, Christine M. Lovly, Gary Dukart, Kimberly Harrow, Chris Liang, James J. Gibbons, Leora Horn	3
16	MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC 2016 ·Journal of Thoracic Oncology ·Leora Horn, Heather A. Wakelee, Karen L. Reckamp, George R. Blumenschein, Jeffrey R. Infante, Corey A. Carter, Saiama N. Waqar, Joel W. Neal, Kimberly Harrow, Jon P. Gockerman, Gary Dukart, Chris Liang, J. L. Gibbons, Jennifer Hernandez, (unknown), Lee P. Lim, Christine M. Lovly	7
17	PS01.57: IMpower133: a Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC 2016 ·Journal of Thoracic Oncology ·Leora Horn, Martin Reck, Tony Mok, Melissa L. Johnson, Xiongwen Tang, Sivuonthanh Lam, Daniel Waterkamp, Ariel López-Chávez, Alan N. Sandler, (unknown), Stephen V. Liu	3
18	Oncology Fellows' Career Plans, Expectations, and Well-Being: Do Fellows Know What They Are Getting Into? 2014 ·Journal of Clinical Oncology ·Tait D. Shanafelt, Marilyn Raymond, Leora Horn, (unknown), Frances A. Collichio, Helen K. Chew, Michael P. Kosty, Daniel Satele, Jeff A. Sloan, William J. Gradishar	46
19	DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy 2013 ·Clinical Cancer Research ·Paul G. Yeh, Heidi Chen, J. M. Andrews, (unknown), William Pao, Leora Horn	78
20	Identifying Barriers Associated With Enrollment of Patients With Lung Cancer into Clinical Trials 2012 ·Clinical Lung Cancer ·Leora Horn, Vicki L. Keedy, Norma Campbell, (unknown), (unknown), (unknown), David P. Carbone, Alan Sandler, David H. Johnson	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact